Astellas Pharma

Global Aging And Personalized Medicine Will Open Therapeutic Markets

AnalystHighTarget

Not Invested

Community Contributor

Published

09 Jun 25

AnalystHighTarget's Fair Value

JP¥2,200.00

26.3% undervalued

10 Sep

JP¥1,621.00

-7.4%

-0.2%

-7.4%

-0.2%

You can edit this narrative until Jun 9 9:10 PM. Then, changes will post as Updates.

Author's Valuation

JP¥2.2k26.3% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

JP¥2.2k

26.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

-3.60%

Pharma revenue growth rate

0.67%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

4.72%

Calculation

JP¥332.26b

Earnings '28

13.61x

PE Ratio '28

JP¥4.52t

Market Cap '28

JP¥4.52t

Market Cap '28

1.79b

No. shares '28

JP¥2.53k

Share Price '28

JP¥2.53k Share Price '28

Discounted to 2025 @ 4.72% p.a.

JP¥2.20k

Fair Value '25